New tuberculosis therapeutics: A growing pipeline

Journal of Infectious Diseases

Volumn 196, Issue SUPPL. 1, 2007, Pages

  Spigelman, Melvin K ^a  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; CGI 17341; CYTOCHROME P450 ISOENZYME; DIAMINE DERIVATIVE; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LL 3858; MACROLIDE; MOXIFLOXACIN; NITROIMIDAZOLE DERIVATIVE; OFLOXACIN; OPC 67683; OXAZOLIDINONE DERIVATIVE; PLEUROMUTILIN; PROTEINASE INHIBITOR; PYRAZINAMIDE; PYRIDONE DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SQ 109; TMC 207; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DEVELOPING COUNTRY; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUPERINFECTION; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADAMANTANE; ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS; DIAMINES; ETHYLENEDIAMINES; FLUOROQUINOLONES; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; QUINOLINES; TUBERCULOSIS;

EID: 34547619993     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/518663     Document Type: Conference Paper

References (37)

1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-21.
2. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Resp Crit Care Med 2003; 167:603-62.
3. World Health Organization (WHO). World Health Organization Global Tuberculosis Programme: global tuberculosis control. WHO/GTB/97.225. Geneva: WHO, 1997.
4. Tuberculosis Research Centre (Indian Council of Medical Research), Chennai. Shortening short course chemotherapy: a randomized clinical trial for the treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian Journal of Tuberculosis 2002; 49:27-38.
5. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993; 147:1062-3.
6. Mitchison DA. Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. Soc Appl Bacteriol Symp Ser 1996; 25:S72-80.
7. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 2002; 360:528-34.
8. Miyazaki E, Miyazaki M, Chan JM, Chaissson RE, Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999; 43:85-9.
9. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Animicrob Agents Chemother 2002; 46:1875-9.
10. Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D. In vitro antibacterial spectrum of a new broad-spectrum 8- methoxyfluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000; 45:437-46.
11. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46:1022-5.
12. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:653-7.
13. Lounis N, Bentoucha A, Truffot-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001; 45:3482-6.
14. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004; 170:1131-4.
15. Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168:1342-5.
16. Pletz MW, Deroux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48:780-2.
17. Lienhardt C, Rustomjee R, Allen J, et al. Comparison of 2-months sterilizing activities of several quinolone-containing regimens: preliminary results of a phase II trial in South Africa [abstract LB2-13]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005:205.
18. Burman WJ, Johnson J, Goldberg S, et al. Moxifloxacin vs. ethambutol in multidrug treatment of pulmonary tuberculosis - final results of a randomized double-blind trial [abstract LB-31]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005:203.
19. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223-7.
20. Huitric EG, Andries K, Hoffner SES. MIC distribution of R207910: an in vitro study on drug-susceptible and drug-resistant Mycobacterium tuberculosis [abstract F-1477]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005:208.
21. Zhu M, Lounis N, Timmerman P, Jarlier V, Andries K. Pharmacokinetic and pharmcodynamic analysis of R207910 in a murine model of M. tuberculosis [abstract A-435]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005:14.
22. Stover CK, Warrener P, VanDevanter DR, et al: A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405:962-6.
23. Ginsberg A, Spigelman M. New drugs for tuberculosis. In: Reichman L, Hershfield E, eds. Tuberculosis: a comprehensive international approach. 3rd ed. New York and London: Informa Healthcare, 2006:1135-51.
24. Spigelman MK. Current and future therapeutic options for tuberculosis [presentation 2190 in symposium 220{F}]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005:115.
25. Manjunatha UH, Boshoff H, Dowd CS, et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Nat Acad Sci USA 2006; 103:431-6.
26. Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in the murine model of tuberculosis. Antimicrob Agents Chemother 2005; 49:2289-93.
27. Matsumoto M, Hshizume H, Tomishige T, Kawasaki M. In vitro and in vivo efficacy of novel antituberculous candidate OPC-67683 [abstract F-1462]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005:204.
28. Tsubouchi H, Sasaki H, Haraguchi Y, et al. Synthesis and antituberculous activity of a novel series of optically active 6-nitro-2,3-dihydroimidazol[2,1- b]oxazoles [abstract F-1473]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005:207.
29. Kawasaki M, Yamamoto K, Matusmoto M. Mechanism of action of OPC-67683 against Mycobacterium tuberculosis [abstract F-1463]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005:204.
30. Hashizume H, Ohguro K, Itoh T, et al. OPC-67683, a novel imidazo-oxazole antituberculous compound, free from mutagenicity: structure-activity- mutagenesity relationships [abstract F-1464]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005:204.
31. Deidda D, Lampis G, Fioravanti R, et al. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 1998; 2:3035-7.
32. Arora SK, Sinha N, Sinha RK, Uppadhayaya RS, Modak VM, Tilekar A. Synthesis and in vitro anti-mycobacterial activity of a novel anti-TB composition LL4858 [abstract F-1115]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004:212.
33. Sinha RK, Arora SK, Sinha N, Modak VM. In vivo activity of LL4858 against Mycobacterium tuberculosis [abstract F-1116]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004:212.
34. Lee R, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE III. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem 2003; 5:172-87.
35. Jia L, Tomaszewski JE, Hanrahan C, et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005; 144:80-7.
36. Mitchison DA. The search for new sterilizing anti-tuberculosis drugs. Front Biosci 2004; 9:1059-72.
37. Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid: a Medical Research Council Investigation. Br Med J 1950; 2:1073-85.